International Stem CellISCO -10.50%24 Current Ratio is 0.76 as of Mar. 2026, which is 4% above its 10-year median of 0.73. GuruFocus rates ISCO with a GF Score™ of 24/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,410 Biotechnology companies, International Stem Cell ranks worse than 87.66% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. International Stem Cell's current ratio for the quarter that ended in Mar. 2026 was 0.76.
International Stem Cell has a current ratio of 0.76. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If International Stem Cell has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for International Stem Cell's Current Ratio or its related term are showing as below:
ISCO'
s Current Ratio Range Over the Past 10 Years
Min: 0.38 Med: 0.73 Max: 1.8
Current: 0.76
During the past 13 years, International Stem Cell's highest Current Ratio was 1.80. The lowest was 0.38. And the median was 0.73.
ISCO's Current Ratio is ranked worse than 87.66% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs ISCO: 0.76
International Stem Cell (OTCPK:ISCO) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
International Stem Cell Current Ratio Related Terms
International Stem Cell Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISCO vs ZVSA, AXIM, HEPA: Current Ratio Comparison
For the Biotechnology subindustry, International Stem Cell's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's Current Ratio distribution charts can be found below:
* The bar in red indicates where International Stem Cell's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell (ISCO) has a Current Ratio of 0.76 as of Mar. 2026. This is near median its historical median of 0.73. Over the past decade, International Stem Cell's Current Ratio has ranged from 0.38 to 1.80. According to the industry distribution chart, International Stem Cell ranks #1236 out of 1410 companies in the Biotechnology industry, placing it in the top 87.7%.
Is International Stem Cell's Current Ratio too high?
International Stem Cell's current Current Ratio of 0.76 is near median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 1.80. The Biotechnology industry median Current Ratio is 3.89. International Stem Cell's value of 0.76 is 80.5% below this industry median. Based on the distribution chart, International Stem Cell ranks #1236 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, International Stem Cell has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Current Ratio compare to ZVSA and AXIM?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #1236 out of 1410 companies for Current Ratio. This places International Stem Cell in the lower half of its industry. The industry median Current Ratio is 3.89. International Stem Cell's value of 0.76 is 80.5% below this benchmark. Historically, International Stem Cell's own Current Ratio has ranged from 0.38 to 1.80 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 3.89, International Stem Cell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. International Stem Cell's current Current Ratio of 0.76 is 80.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. International Stem Cell's current Current Ratio is 0.76, which is near median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 37.7% above its estimated fair value. The current Current Ratio is 0.76, which is near median its 10-year median of 0.73 and 80.5% below the Biotechnology industry median of 3.89. International Stem Cell's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Current Ratio is 0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Stem Cell (ISCO) Overvalued in 2026?
Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued.
The current stock price of $0.18 is trading 37.7% above its estimated GF Value™ of $0.13.
GuruFocus considers International Stem Cell to be Significantly Overvalued.
Key valuation signals for ISCO:
Current Ratio: 0.76 (near median its 10-year median of 0.73)
GF Value™: $0.13 vs. price of $0.18 (37.7% above fair value)
Industry Position: 80.5% below the Biotechnology median (#1236 of 1410)
No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
24GF Score
Get the complete analysis for ISCO
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISCO has been successfully added to your 
